Skip to main content
SpringerLink
Log in

Current and future therapy of chronic hepatitis

  • Chapter
Pharmacotherapy of Gastrointestinal Inflammation

Part of the book series: Progress in Inflammation Research ((PIR))

  • 109 Accesses

Abstract

Among the different types of viral infections affecting the liver, hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis delta virus (HDV) represent the major pathogens currently shown to cause chronic hepatitis. This condition implies persistence of viral infection and secondary inflammation for more than six months after initial exposure. Autoimmune hepatitis is a self-perpetuating hepatocellular inflammation characterized by specific histologic lesions and liver-associated auto-antibodies. Alcoholic hepatitis is a frequent condition in the Western world, due to excessive alcohol consumption and progressing to cirrhosis, especially in subjects who continue to abuse ethanol. This chapter focuses on current therapeutic options and novel strategies for the treatment of these conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lok AS, McMahon BJ (2001) Chronic hepatitis B. Hepatology 34: 1225–1241

    Article  PubMed  CAS  Google Scholar 

  2. Liaw YF (2002) Therapy of chronic hepatitis B: Current challenges and opportunities. JViral Hepat 9: 393–399

    Article  Google Scholar 

  3. Perry CM, Wagstaff AJ (1998) Interferon-a-nl: A review of its pharmacological prop-erties and therapeutic efficacy in the management of chronic viral hepatitis. Biodrugs 9: 125–154

    Article  PubMed  CAS  Google Scholar 

  4. Mallat A, Preaux AM, Blazejewski S, Rosenbaum J, Dhumeaux D, Mavier P (1995) Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology 21: 1003–1010

    Article  PubMed  CAS  Google Scholar 

  5. Wong DK, Cheung AM, O’Rourke K, Naylor CD, Detsky AS, Heathcote J (1993) Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 119: 312–323

    PubMed  CAS  Google Scholar 

  6. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Häussinger D (1996) Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334: 1422–1427

    Article  PubMed  CAS  Google Scholar 

  7. Pramoolsinsup C (2002) Management of viral hepatitis B. J Gastroenterol Hepatol 17 (Suppi): S126–S146

    Google Scholar 

  8. Jarvis B, Faulds D (1999) Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs 58: 101–141

    Article  PubMed  CAS  Google Scholar 

  9. Noble S, Goa KL (1999) Adefovir dipivoxil. Drugs 58: 479–487

    Article  PubMed  CAS  Google Scholar 

  10. Yang H, Westland CE, Delaney IV WE, Heathcote EJ, Ho V, Fry J, Brosgart C, Gibbs CS, Miller MD, Xiong S (2002) Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 36: 464–473

    Article  PubMed  CAS  Google Scholar 

  11. McClellan MB (2002) New drug for hepatitis B. JAMA 288: 2112

    Article  PubMed  Google Scholar 

  12. Chan HL, Tang JL, Tam W, Sung JJY (2001) The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment Pharmacol Ther 15: 1899–1905

    Article  PubMed  CAS  Google Scholar 

  13. Heathcote J, McHutchison J, Lee S, Tong M, Benner K, Minuk G, Wright T, Fikes J, Livingston B, Sette A et al (1999) A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. Hepatology 30: 531–536

    Article  PubMed  CAS  Google Scholar 

  14. Galun E, Eren R, Safadi R, Ashour Y, Terrault N, Keeffe EB, Matot E, Mizrachi S, Terkieltaub D, Zohar M et al (2002) Clinical evaluation (Phase I) of a combination of two human monoclonal antibodies to HBV: Safety and antiviral properties. Hepatology 35: 673–679

    Article  PubMed  CAS  Google Scholar 

  15. Artillo S, Pastore G, Alberti A, Milella M, Santantonio T, Fattovich G, Giustina G, Ryff JC, Chaneac M, Bartolomé J et al (1998) Double-blind, randomized controlled trial of interleukin-2 treatment of chronic hepatitis B. J Med Virol 54: 167–172

    Article  PubMed  CAS  Google Scholar 

  16. Zeuzem S, Carreno V (2001) Interleukin-12 in the treatment of chronic hepatitis B and C. Antiviral Res 52: 181–188

    Article  PubMed  CAS  Google Scholar 

  17. von Weizsacker F, Wieland S, Kock J, Offensperger WB, Offensperger S, Moradpour D, Blum HE (1997) Gene therapy for chronic viral hepatitis: Ribozymes, antisense oligonucleotides, and dominant negative mutants. Hepatology 26: 251–255

    Article  Google Scholar 

  18. Rivkina A, Rybalov S (2002) Chronic hepatitis B: Current and future treatment options. Pharmacotherapy 22: 721–737

    Article  PubMed  CAS  Google Scholar 

  19. Ying C, De Clercq E, Nicholson W, Furman P, Neyts J (2000) Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat 7: 161–165

    Article  PubMed  CAS  Google Scholar 

  20. van Bömmel F, Wünske T, Schürmann D, Berg T (2002) Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 36: 507–508

    Article  PubMed  Google Scholar 

  21. Hadziyannis SJ (1999) Hepatitis D. Clin Liver Dis 3: 309–319

    Article  Google Scholar 

  22. Yalcin K, Degertekin H, Yildiz F, Akkus Z (2002) A 12-month course of combination therapy with interferon-alfa and lamivudine in patients with chronic hepatitis delta virus: a single-center, prospective, open-label, uncontrolled study. Curr Ther Res Clin Exp 63: 736–747

    Article  CAS  Google Scholar 

  23. Beccarello A, Bortolato L, Triches C, Paleari C, Awasum MC, Zalunardo B, Orlando R, Lirussi F (2002) Monoethylglycinexylidide kinetics and galactose elimination capacity during treatment with interferon-alfa for hepatitis C virus infection: Possible predictors of response? Curr Ther Res Clin Exp 63: 772–785

    Article  CAS  Google Scholar 

  24. Lirussi F, Beccarello A, Castiglione G, Guglietta A (2002) Impaired natural killer cell cytotoxic activity in chronic hepatitis C viral infection: A single-center, controlled study. Curr Ther Res Clin Exp 63: 748–758

    Article  Google Scholar 

  25. Lau JY, Tam RC, Liang TJ, Hong Z (2002) Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35: 1002–1009

    Article  PubMed  CAS  Google Scholar 

  26. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358: 958–965

    Article  PubMed  CAS  Google Scholar 

  27. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D et al (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975–982

    Article  PubMed  CAS  Google Scholar 

  28. Khurshudian AV (2003) A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjogren’s syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95: 38–44

    Article  PubMed  Google Scholar 

  29. Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX, Garcia A, Moody G, Zaritskaya LS, Sung C (2003) Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 303: 540–548

    Article  Google Scholar 

  30. Watson J (2002) Prospects for hepatitis C virus therapeutics: Levovirin and viramidine as improved derivatives of ribavirin. Curr Opin Investig Drugs 3: 680–683

    PubMed  CAS  Google Scholar 

  31. McHutchison JG, Patel K (2002) Future therapy of hepatitis C. Hepatology 36 (Suppl 1): S245–S252

    Article  PubMed  Google Scholar 

  32. Firpi RJ, Nelson DR, Davis GL (2003) Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection. Liver Transpl 9: 57–61

    Article  PubMed  Google Scholar 

  33. Lurie Y, Nevens F, Aprosina ZG, Fedorova TA, Kalinin AV, Klimova EA, Ilan Y, Maevskaya MV, Warnes TW, Yuschuk ND et al (2002) A multicentre, randomized study to evaluate the safety and efficacy of histamine dihydrochloride and interferon-alpha-2b for the treatment of chronic hepatitis C. J Viral Hepat 9: 346–353

    Article  PubMed  CAS  Google Scholar 

  34. Pockros PJ (2002) Developments in treatment of chronic hepatitis C. Expert Opin Invest Drugs 11: 1–14

    Article  Google Scholar 

  35. Nelson DR, Lauwers GY, Lau JY, Davis GL (2000) Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: A pilot trial of interferon non-responders. Gastroenterology 118: 655–660

    Article  PubMed  CAS  Google Scholar 

  36. Frese M, Schwarzle V, Barth K, Krieger N, Lohmann V, Mihm S, Haller O, Bartenschlager R (2002) Interferon-gamma inhibits replicaton of subgenomic and genomic hepatitis C virus RNAs. Hepatology 35: 694–703

    Article  PubMed  CAS  Google Scholar 

  37. Lirussi F, Beccarello A, Bortolato L, Morselli-Labate AM, Crovatto M, Ceselli S, Santini G, Crepaldi G (1999) Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: Influence of HCV genotypes and severity of liver disease. Liver 19: 381–388

    Article  PubMed  CAS  Google Scholar 

  38. Czaja AJ, Freese DK (2002) Diagnosis and treatment of autoimmune hepatitis. Hepatology 36: 479–497

    Article  PubMed  Google Scholar 

  39. Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G (2002) Pathogenesis of autoimmune hepatitis. Clin Liver Dis 6: 727–737

    Article  PubMed  Google Scholar 

  40. Soloway RD, Summerskill WH, Baggenstoss AH, Geall MG, Gitnick GL, Elveback LR, Schoenfield LJ (1972) Clinical, biochemical, and histological remission of severe chronic active liver disease: A controlled study of treatments and early prognosis. Gastroenterology 63: 820–833

    PubMed  CAS  Google Scholar 

  41. Summerskill WH, Korman MG, Ammon HV, Baggenstoss AH (1975) Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 16: 876–883

    Article  PubMed  CAS  Google Scholar 

  42. Heneghan MA, McFarlane IG (2002) Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 35: 7–13

    Article  PubMed  CAS  Google Scholar 

  43. Vierling JM, Flores PA (2002) Evolving new therapies of autoimmune hepatitis. Clin Liver Dis 6: 825–850

    Article  PubMed  Google Scholar 

  44. Czaja AJ (2002) Treatment of autoimmune hepatitis. Seminar Liver Dis 22 (4): 365–378

    Article  CAS  Google Scholar 

  45. Danielsson A, Prytz H (1994) Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 8: 585–590

    Article  PubMed  CAS  Google Scholar 

  46. Czaja AJ, Lindor KD (2000) Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 119: 1312–1316

    Article  PubMed  CAS  Google Scholar 

  47. Rebollo Bernardez J, Cifuentos Mimoso C, Pinar Moreno A, Caunedo Alvarez A, Salas Herrero E, Jiminez-Saenz M, Herrerias Gutierrez J (1999) Deflazacort for long-term maintenance of remission in type 1 autoimmune hepatitis. Rev Esp Enferm Dig 91: 630–638

    PubMed  CAS  Google Scholar 

  48. Czaja AJ (2002) Treatment strategies in autoimmune hepatitis. Clin Liver Dis 6: 799–824

    Article  PubMed  Google Scholar 

  49. Pratt DS, Flavin DP, Kaplan MM (1996) The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology 110: 271–274

    Article  PubMed  CAS  Google Scholar 

  50. Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, Taheri H, Kamalian N, Sotoudeh M (2001) Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 46: 1321–1327

    Article  PubMed  CAS  Google Scholar 

  51. van Thiel DH, Wright H, Carroll P, Abu-Elmagd K, Rodriguez-Rilo H, McMichael J, Irish W, Starzl TE (1995) Tacrolimus: A potential new treatment for autoimmune chron-ic active hepatitis: Results of an open-label preliminary trial. Am J Gastroenterol 90: 771–776

    PubMed  Google Scholar 

  52. Richardson PD, James PD, Ryder SD (2000) Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 33: 371–375

    Article  PubMed  CAS  Google Scholar 

  53. Kanzler S, Gerken G, Dienes HP, Meyer zum Buschenfelde KH, Lohse AW (1997) Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis — Report of three cases. Z Gastroenterol 35: 571–578

    CAS  Google Scholar 

  54. Burak KW, Urbanski SJ, Swain MG (1998) Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 29: 990–993

    Article  PubMed  CAS  Google Scholar 

  55. Stern RB, Wilkinson SP, Howorth PJ, Williams R (1977) Controlled trial of synthetic Dpenicillamine and prednisone in maintenance therapy for active chronic hepatitis. Gut 18: 19–22

    Article  PubMed  CAS  Google Scholar 

  56. McClements BM, Callender ME (1990) D-penicillamine therapy in patients with HBsAg-negative chronic active hepatitis and major prednisolone-induced adverse effects. J Hepatol 11: 322–325

    Article  PubMed  CAS  Google Scholar 

  57. Lirussi F, Okolicsanyi L (1992) Cytoprotection with ursodeoxycholic acid: Effect in chronic non-cholestatic and chronic cholestatic liver disease. Ital J Gastroenterol 24: 31–35

    PubMed  CAS  Google Scholar 

  58. Calmus Y, Gane P, Rouger P, Poupon R (1990) Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: Effect of ursodeoxycholic acid. Hepatology 11: 12–15

    Article  PubMed  CAS  Google Scholar 

  59. Nakamura K, Yoneda M, Yokohama S, Tamori K, Sato Y, Aso K, Aoshima M, Hasegawa T, Makino I (1998) Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 13: 490–495

    Article  PubMed  CAS  Google Scholar 

  60. Czaja AJ, Carpenter HA, Lindor KD (1999) Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: A randomized placebo-controlled treatment trial. Hepatology 30: 1381–1386

    Article  PubMed  CAS  Google Scholar 

  61. Fulton S, McCullough AJ (1998) Treatment of alcoholic hepatitis. Clin Liver Dis 2: 799–819

    Article  Google Scholar 

  62. Imperiale TF, McCullough AJ (1990) Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 113: 299–307

    PubMed  CAS  Google Scholar 

  63. McCullough AJ, O’Connor JF (1998) Alcoholic liver disease: Proposed recommendations for the American college of gastroenterology. Am J Gastroenterol 93: 2022–2036.

    Article  CAS  Google Scholar 

  64. Christensen E, Gluud C (1995) Glucocorticoids are ineffective in alcoholic hepatitis: A meta-analysis adjusting for confounding variables. Gut 37: 113–118

    Article  PubMed  CAS  Google Scholar 

  65. Mathurin P, Duchatelle V, Ramond MJ, Degott C, Bedossa P, Erlinger S, Benhamou JP, Chaput JC, Ruett B, Poynard T (1996). Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 110: 1847–1853

    Article  PubMed  CAS  Google Scholar 

  66. Marchesini G, Bianchi G, Fabbri A (1998) Long-term management of alcoholic liver disease. Clin Liver Dis 2: 821–838

    Article  Google Scholar 

  67. Cabré E, Rodríguez-Iglesias P, Caballería J, Quer JC, Sánchez-Lombrana JL, Parés A, Papo M, Planas R, Gassull MA (2000) Short-and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: A multicenter randomized trial. Hepatology 32: 36–42

    Article  PubMed  Google Scholar 

  68. Colell A, Garcia-Ruiz C, Miranda M, Ardite E, Mari M, Morales A, Corrales F, Kaplowitz N, Fernandez-Checa JC (1998) Selective glutathione depletion of mitochondria by ethanol sensitizes hepatocytes to tumor necrosis factor. Gastroenterology 115: 1541–1551

    Article  PubMed  CAS  Google Scholar 

  69. Kono H, Rusyn I, Yin M, Gabele E, Yamashina S, Dikalova A, Kadiiska MB, Connor HD, Mason RP, Segal BH, et al (2000) NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease. J Clin Invest 106: 867–872

    Article  PubMed  CAS  Google Scholar 

  70. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil 0 (2000) Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebo-controlled trial. Gastroenterology 119: 1637–1648

    Article  PubMed  CAS  Google Scholar 

  71. Maher JJ (2002) Treatment of alcoholic hepatitis. J Gastroenterol Hepatol 17: 448–455

    Article  PubMed  CAS  Google Scholar 

  72. Rambaldi A, Gluud C (2001) Meta-analysis of propylthiouracil for alcoholic liver disease — A Cochrane hepato-biliary group review. Liver 21: 398–404

    Article  PubMed  CAS  Google Scholar 

  73. Sogni P, Hadengue A, Moreau R, Le moine 0, Soupison T, Oberti F, Farinotti R, Lebrec D (1997) Acute effects of propylthiouracil on hemodynamics and oxygen content in patients with alcoholic cirrhosis. J Hepatol 26: 628–633

    CAS  Google Scholar 

  74. Ross AD, Dey I, Janes N, Israel Y (1998) Effect of antithyroid drugs on hydroxyl radical formation and alpha-1-proteinase inhibitor inactivation by neutrophils: Therapeutic implications. J Pharmacol Exp Ther 285: 1233–1238

    PubMed  CAS  Google Scholar 

  75. Mato JM, Camara J, Fernandez de Paz J, Caballería L, Coll S, Caballero A, Garcia-Buey L, Beltran J, Benita V, Caballería J et al (1999) S-adenosylmethionine in alcoholic liver cirrhosis: A randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 30: 1081–1089

    Article  PubMed  CAS  Google Scholar 

  76. Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, Meryn S, Base W, Schneider B (1989) Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 9: 105–113

    Article  PubMed  CAS  Google Scholar 

  77. Parés A, Planas R, Torres M, Caballería J, Viver JM, Acero D, Panés J, Rigau J, Santos J, Rodés J (1998) Effects of silymarin in alcoholic patients with cirrhosis of the liver: Results of a controlled, double-blind, randomized and multicenter trial. J Hepatol 28: 615–621

    Article  PubMed  Google Scholar 

  78. Kershenobich D, Vargas F, Garcia-Tsao G, Perez Tamayo R, Gent M, Rojkind M (1988) Colchicine in the treatment of cirrhosis of the liver. N Engl J Med 318: 1709–1713

    Article  PubMed  CAS  Google Scholar 

  79. Rambaldi A, Gluud C (2001) Colchicine for alcoholic and non-alcoholic liver fibrosis or cirrhosis. Liver 21: 129–136

    Article  PubMed  CAS  Google Scholar 

  80. Cortez-Pinto H, Alexandrino P, Camilo ME, Gouveia-Oliveira A, Santos PM, Alves MM, Moura MC (2002) Lack of effect of colchicine in alcoholic cirrhosis: Final results of a double blind randomized trial. Eur J Gastroenterol Hepatol 14: 377–381

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical and Surgical Sciences, University of Padua, Via Giustiniani 2, 35128, Padova, Italy

    Flavio Lirussi & Beniamino Zalunardo

Authors
  1. Flavio Lirussi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Beniamino Zalunardo
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Grupo Ferrer Internacional, C./Juan de Sada 32, 08028, Barcelona, Spain

    Antonio Guglietta (R&D Director) (R&D Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Basel AG

About this chapter

Cite this chapter

Lirussi, F., Zalunardo, B. (2004). Current and future therapy of chronic hepatitis. In: Guglietta, A. (eds) Pharmacotherapy of Gastrointestinal Inflammation. Progress in Inflammation Research. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-7930-9_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-7930-9_3

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9625-2

  • Online ISBN: 978-3-0348-7930-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation